|
2-(butylamino)quinolin-8-ol |
|
Brucella |
VirB type IV secretion system |
Preclinical (in vivo) |
Paschos A, et al. 2011. Infect Immun; Smith MA, et al. 2012. Chem Biol |
|
7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine |
Depiction based on curated SMILES
NH
2
N
B
CH
3
CH
3
CH
3
H
3
C
O
O
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
N-(4-amino-2-methyl-6-quinolinyl)-N-{2-[(4-amino-2-methyl-6-quinolinyl)amino]-6-methyl-4-pyrimidinyl}amine |
Depiction based on curated SMILES
N
NH
N
CH
3
NH
2
N
CH
3
NH
2
H
3
C
N
N
H
|
Salmonella |
TTSS (SPI-1 encode) |
Preclinical (in vitro) |
von Ambüren J, et al. 2020. Microorganisms |
|
4-Aminoquinaldine |
Depiction based on curated SMILES
CH
3
NH
2
N
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dey S, et al. 2017. ChemMedChem |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |